News

News

May 27, 2021
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
SAN DIEGO , May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that
April 22, 2021
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development , to Obtain FDA Approval $20MM Milestone Payment Earned by AnaptysBio Upon FDA Approval; Additional $45MM
April 12, 2021
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
SAN DIEGO , April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the
Displaying 1 - 10 of 13